BioPharmSignal logoBioPharmSignal

Biotech News

Pliant Therapeutics Provides Corporate Update and Reports First Quarter 2026 Financial Results

Pliant Therapeutics (PLRX)Pliant TherapeuticsEarnings

First participant dosed in FORTIFY, a Phase 1b indication expansion trial of PLN-101095 Oral presentation at AACR 2026 featured updated data from Phase 1 trial of PLN-101095 showing deepening of confirmed responses in checkpoint inhibitor-refractory solid tumors PLN-101095 spotlighted as novel IO

Related news

PLRXPliant Therapeutics2026-08-11 20:05 EST

Pliant Therapeutics Provides Corporate Update and Reports Second Quarter 2026 Financial Results

PLRXPliant Therapeutics2026-03-11 20:05 EST

Pliant Therapeutics Provides Corporate Update and Reports Fourth Quarter 2025 Financial Results

View all latest news

Pliant Therapeutics

Integrin-Targeted Drug Discovery Pliant Therapeutics is a clinical-stage biotechnology company developing therapies that modulate integrin-mediated biological pathways. Its current development focus centers on oncology and targeted drug delivery. PLN-101095 PLN-101095 is an oral small molecule that selectively inhibits the αvβ8 and αvβ1...

Recent company news

PLRXPliant Therapeutics2026-08-18 12:30 EST

Pliant Therapeutics Receives FDA Fast Track Designation for PLN-101095 in Combination with Pembrolizumab for the Treatment of ICI-Refractory Solid Tumors

PLRXPliant Therapeutics2026-08-11 20:05 EST

Pliant Therapeutics Provides Corporate Update and Reports Second Quarter 2026 Financial Results

PLRXPliant Therapeutics2026-07-13 12:30 EST

Pliant Therapeutics Names Flavia Borellini, Ph.D. and Robert Iannone, M.D., M.S.C.E. to Board of Directors

PLRXPliant Therapeutics2026-05-21 21:30 EST

Pliant Therapeutics Announces Upcoming Presentation at the 2026 American Society of Clinical Oncology Annual Meeting

PLRXPliant Therapeutics2026-05-11 20:05 EST

Pliant Therapeutics Provides Corporate Update and Reports First Quarter 2026 Financial Results

Stock data

Close
1.10 USD
Market cap
71.83M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States